Immune Modulator Drugs Improved Survival for People Hospitalized with COVID-19
SC CTSI collaborated with the National Center for Advancing Translational Sciences and other CTSAProgram hubs to implement The National Institutes of Health’s ACTIV-1 Immune Modulators Clinical Trial.
As part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private initiative, NIH launched the ACTIV-1 Immune Modulators clinical trial to determine if certain drugs that help minimize the effects of an overactive immune response could speed recovery and reduce deaths in adults hospitalized with moderate to severe COVID-19. Preliminary results from the trial showed that infliximab or abatacept did not significantly shorten time to recovery but did substantially improve clinical status and reduce deaths.
NCATS coordinated and oversaw the trial with funding from Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. More than thirty CTSA Program Hubs and the Trial Innovation Network played a key role in enrolling participants in the United States and contributing their infrastructure and expertise to the trial. Read the news release to learn more about the preliminary results: https://go.usa.gov/xJjMk
More info:
- NIH ACTIV: Accelerating COVID-19 Therapeutic Interventions and Vaccines
- Introduction of ACTIV-1 Immune Modulators clinical trial: NIH Begins Large Clinical Trial to Test Immune Modulators for Treatment of COVID-19
